Company profile
Vor Biopharma Inc.
NASDAQ:VORBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TELITACICEPT | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06456580 | phase3 | recruiting | 2024-07-17 | 2027-05-01 | Vor Biopharma | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) |
| NCT05306574 | phase3 | terminated | 2022-06-20 | 2025-01-06 | Vor Biopharma | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) |
| NCT06456567 | phase3 | withdrawn | 2024-09-01 | 2025-01-02 | Vor Biopharma | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2) |
| NCT04849910 | phase1_2 | terminated | 2021-12-16 | 2025-05-28 | Vor Biopharma | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS |
| NCT05984199 | phase1_2 | terminated | 2023-12-11 | 2025-05-28 | Vor Biopharma | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant |
FDA applications (0)
No records yet.